Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Aug;99(8):e145-6.
doi: 10.3324/haematol.2013.103135.

The challenge of cross-trial comparisons using limited data

Jacob P Laubach  1 , Edward A Faber Jr  2 , Peter Voorhees  3 , Javid Moslehi  4 , Cindy Varga  1 , Liviu Niculescu  5 , Kenneth C Anderson  1 , Paul G Richardson  6
Affiliations
Comment

The challenge of cross-trial comparisons using limited data

Jacob P Laubach et al. Haematologica. 2014 Aug.
No abstract available

Keywords: challenge; cross-trial; data.

PubMed Disclaimer

Comment in

Comment on

References

    1. Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, et al. Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase 2 clinical studies. Haematologica. 2013;98(11):1753–61 - PMC - PubMed
    1. KYPROLIS™ (carfilzomib), for injection, for intravenous use. Prescribing information. Onyx Pharmaceuticals Inc; July 2012. Available from: http://www.kyprolis.com/prescribing-information
    1. VELCADE® (bortezomib) for injection. Prescribing information. Revision 15. Millennium Pharmaceuticals Inc; October 2012. Available from: http://www.velcade.com/files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf
    1. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352(24):2487–98 - PubMed
    1. Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, et al. Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013;27(8):1707–14 - PMC - PubMed

MeSH terms